An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

About the trial

Sponsor

Jonsson Comprehensive Cancer Center (with Blue Earth Diagnostics)

Tested

Computed Tomography (procedure), Fluorine F 18 Flotufolastat (drug), Positron Emission Tomography (procedure), Ultrasound-Guided Prostate Biopsy (procedure)

Dates

Started 2025-10-09; completion 2036-10-25

Results posted

Not yet

This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufo…

From ClinicalTrials.gov, last updated 2026-09-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Blue Earth Diagnostics reported $5,066 in research payments for this study in 2025 (1 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.